Company Highlights
- Silo Wellness is a psychedelic wellness company with a parallel track focusing on developing wellness facilities and a psilocybin- or derivative-based treatment.
- Silo Wellness is the only publicly traded company with an operational foothold in Oregon that replicates its proof of concept for psilocybin in Jamaica.
- The company’s Jamaican psychedelic wellness retreats provide a current revenue stream.
- An experienced team of managers and scientists lead the company towards its goals of widespread treatment with psilocybin-based treatments.
- Silo Wellness recently acquired 100 percent of Dyscovry Science Ltd., a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting irritable bowel syndrome.
Overview
Psychedelics have long been believed to have medicinal value, and now a growing body of research supports that theory. Johns Hopkins has published over 60 peer-reviewed studies on the topic, reflecting research into how psychedelics can impact behavior, cognition and brain function. The University of Texas even opened a new center to study how psychedelics can be used to treat depression, PTSD and anxiety. Research paved the way for the cannabis industry, and now psychedelics are not far behind.
In the US, Oregon became the first state to legalize psychedelics in 2020 with Measure 109 for medicinal administration, and now other states are following suit. US Rep. Alexandria Ocasio-Cortez also filed a measure to remove a 90s-era provision on psychedelics. While it was rejected, the vote has never been closer — a sign that we may see the federal government reducing its restrictions on psychedelics soon. Companies pursuing the field of psychedelic medical treatment now are poised for success as legal barriers are removed, either at the state or federal level.
Silo Wellness (CSE:SILO, OTCQB:SILFF) is a psychedelic wellness company pursuing two parallel tracks to capitalize on the growing market fully. First, biotech research represents its long-term track, with the second track focusing on providing services in jurisdictions where legal barriers have been removed. The company, which was founded in Oregon by an Oregon lawyer, has previously launched Oregon’s first legal psychedelic retreats via ketamine (also a U.S. legal first). Silo Wellness is pursuing treatment programs in Oregon under Ballot Measure 109 and has a proof-of-concept center in Jamaica. Combined, the company has a unique combination of business lines for both near-term and long-term revenue.
Oregon legalized psilocybin treatment in 2020 and Silo Wellness is the only public company with an established presence in the state. Public companies such as Field Trip and Cybin will not be able to participate directly in the U.S. market due to federal prohibition as that is not allowed by the NASDAQ and NYSE exchanges. In addition to being founded in Oregon, the company is pursuing creating wellness facilities within the state with Oregon legal protection. Additionally, the company presently offers Jamaican psilocybin and 5-Meo-DMT wellness retreats staffed by local experts, including Rastafari Indigenous leaders. The Jamaican retreats are paving the way for the company’s Oregon treatment facilities, creating near-term revenue opportunities and the people, processes, and procedures necessary to safely provide these services in a regulated market.
Silo Wellness recently acquired 100 percent of Dyscovry Science Ltd, a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome. Dyscovry has the IP, facilities, and public collaboration to allow Silo to fully pursue the development of a pharmaceutical treatment platform. The acquisition allows Silo Wellness to further its goal of covering both tracks of the psychedelic industry under one roof: psychedelic healing now via jurisdiction-by-jurisdiction "adult use" and pharmaceutical biotech.
Silo Wellness founder Mike Arnold explained, “Psilocybin mushrooms changed my life. The first thing I thought of after my first dose was, ‘how can I get this treatment into the hands of people in need as quickly as possible?’ We can’t let this plant-based treatment get locked behind long trials and legal restrictions. Not psychedelic healing one day, but psychedelic healing right now.”
The company is led by an experienced team of scientists, researchers, and managers. Silo Wellness has all the right specialists in place to pursue its parallel track and achieve its ambitious goals of legal facilities and psilocybin-based pharmaceutical treatment.
Company Highlights
- Silo Wellness is a psychedelic wellness company with a parallel track focusing on developing wellness facilities and a psilocybin- or derivative-based treatment.
- Silo Wellness is the only publicly traded company with an operational foothold in Oregon that replicates its proof of concept for psilocybin in Jamaica.
- The company’s Jamaican psychedelic wellness retreats provide a current revenue stream.
- An experienced team of managers and scientists lead the company towards its goals of widespread treatment with psilocybin-based treatments.
- Silo Wellness recently acquired 100 percent of Dyscovry Science Ltd., a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting irritable bowel syndrome.
Get access to more exclusive Psychedelics Investing Stock profiles here